The company uses its proprietary Spyglass platform to identify targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 in Phase 1/2 clinical trial in patients with oncogene amplified cancers.
Cyborg Score Rationale
The company has a market cap of $24.4M with EPS (TTM) of -2.66. It is currently unprofitable and not forecast to become profitable over the next 3 years. As a pre-revenue clinical-stage biotech, Boundless Bio faces significant execution and financing risks.
Top Insights
Lead candidate BBI-355 is in Phase 1/2 POTENTIATE trial with proof-of-concept data expected in H2 2025
The Spyglass platform identifies targets essential for ecDNA functionality, representing a novel approach in oncology drug development
Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new kinesin program BBI-940
Company operates with lean workforce of 64 employees
Named Competitors
Checkpoint kinase inhibitors — Traditional oncology checkpoint inhibitors not specifically targeting ecDNA
RNR inhibitors — Ribonucleotide reductase inhibitors for cancer treatment
Recent Developments
(February 2026) Boundless Bio to participate in Guggenheim Emerging Outlook Biotech Summit 2026
(January 2026) Advanced novel kinesin degrader program BBI-940 and extended cash runway
(February 2025) Elected not to advance BBI-825 into Part 2 of STARMAP clinical trial; third ecDTx program advancing
Open the full interactive Boundless Bio, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.